A Phase I/II Study to Assess the Safety, Tolerability, PK/PD, and Preliminary Efficacy of HSK39775 Tablet Monotherapy in Participants With Advanced Solid Malignancies
Latest Information Update: 22 Mar 2024
At a glance
- Drugs HSK 39775 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Haisco Pharmaceutical Group
Most Recent Events
- 22 Mar 2024 New trial record